EPHA2 and breast cancer: As shown in Fig. 5a, b, DR-Exos treated with ALW-II-41-27 still exerted profound migratory promoting ability, which indicated that exosomal EphA2 promoted breast cancer migration through EphA2-Ephrin A1 reverse signaling instead of the kinase-related forward signaling.